Lipocine (LPCN) Receivables - Other (2012 - 2025)

Lipocine (LPCN) has 12 years of Receivables - Other data on file, last reported at $14189.0 in Q4 2025.

• Quarterly Receivables - Other fell 88.22% year-over-year to $14189.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14189.0 (down 88.22% YoY) and the FY2025 annual result came in at $14189.0, down 88.22% from the prior year.
• Receivables - Other retreated to $14189.0 in Q4 2025, from $115272.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $579428.0 in Q3 2022 to a low of $14189.0 in Q4 2025.
• A 5-year average of $214116.6 and a median of $126118.5 in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other jumped 63136.06% — and 2023, when it sank 90.98%.
• Tracing LPCN's Receivables - Other over 5 years: stood at $247253.0 in 2021, then jumped by 134.35% to $579428.0 in 2022, then slumped by 90.98% to $52254.0 in 2023, then surged by 130.5% to $120447.0 in 2024, then plunged by 88.22% to $14189.0 in 2025.
• The last three Receivables - Other figures came in at $14189.0 (Q4 2025), $115272.0 (Q3 2025), and $121732.0 (Q2 2025), per Business Quant data.